Regeneron Pharmaceuticals Inc. outlined its strategic growth plans at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, emphasizing advances in its pipeline and commercial expansion. The company, with a market capitalization of $80.2 billion and a stock price near its 52-week high of $859, delivered a 46% return over the past year. Its price-to-earnings ratio stood at 19.85 as of mid-September 2026.
The focus centered on DUPIXENT, which is projected to annualize at a $24 billion run rate, making it one of the largest pharmaceutical products globally. DUPIXENT, approved for nine indications including atopic dermatitis and eosinophilic esophagitis, serves over 1.5 million patients worldwide. Penetration in atopic dermatitis remains in the high teens, indicating further growth potential. Regeneron’s EYLEA HD franchise, accounting for about 60% of its overall sales, has expanded its market share through label changes and improved dosing regimens.
Regulatory approvals are advancing key programs. Cemdisiran for generalized myasthenia gravis is set for a PDUFA date in November 2026, with a potential launch by year-end. EYLEA HD’s prefilled syringe is nearing approval, while pivotal studies for olatorepatide in obesity and type 2 diabetes are expected to begin by year-end. Additional programs, including a long-acting IL-4 ligand blocker and an IL-4/IL-13 bispecific antibody, are advancing toward clinical entry in 2027, with potential Phase III entry in late 2027 or early 2028.
The company’s Sanofi collaboration, which completed repayment of the development balance in Q2 2026, is being reset to explore expanded opportunities beyond DUPIXENT. Regeneron also in-licensed olatorepatide from Hansoh in 2025 for global rights outside China, with early-stage data suggesting potential advantages in gastrointestinal tolerability compared to GLP-1 drugs. Additionally, Regeneron is reformulating its PCSK9 inhibitor PRALUENT to weekly dosing to complement olatorepatide.
In neurology, Regeneron is developing cemdisiran for generalized myasthenia gravis, targeting a multibillion-dollar market with nine competing products. The company’s C5 complement franchise, combining pozelimab and cemdisiran, is advancing for paroxysmal nocturnal hemoglobinuria and geographic atrophy. Other programs include linvoseltamab for hem-onc, factor XI antibodies for anticoagulation, and early-stage siRNAs for MASH and NPR1-targeted therapy for POTS.
Regeneron’s long-term strategy hinges on proprietary data sets, as highlighted by Ryan Crowe, Head of Investor Relations. The company’s 12-year genetics database linked to electronic health records and a 20-year partnership with Sanofi underscore its foundational strengths in data-driven innovation.
